Depletion of functionally active CD20+ T cells by rituximab treatment

Arthritis and Rheumatism

Volumn 60, Issue 12, 2009, Pages 3563-3571

  Wilk, Esther ^a   Witte, Torsten ^a   Marquardt, Nicole ^a   Horvath, Tibor ^a   Kalippke, Katy ^a   Scholz, Kirsten ^a   Wilke, Nadine ^a   Schmidt, Reinhold E ^a   Jacobs, Roland ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 1BETA; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD20+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD3; APOPTOSIS; BIOLOGICAL MARKERS; CELL PROLIFERATION; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTES, MONONUCLEAR; PHENOTYPE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 73249115641     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24998     Document Type: Article

References (23)

1. Hainsworth JD, Burris HA III, Morrissey LH, Litchy S, Scullin DC Jr, Bearden JD III, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000;95:3052-6.
2. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33.
3. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
4. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359: 242-51.
5. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7.
6. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-8.
7. Dorken B, Moller P, Pezzutto A, Schwartz-Albiez R, Moldenhauer G. B-cell antigens: CD20. In: Knapp W, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, et al, editors. Leucocyte Typing IV. Oxford: Oxford University Press; 1989. p. 46-8.
8. Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20: evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995;270:22632-8.
9. Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003;278: 42427-34.
10. Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 1993;14:196-204.
11. Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G, et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001;31:3121-7.
12. Wendt K, Wilk E, Buyny S, Schmidt RE, Jacobs R. Interleukin-21 differentially affects human natural killer cell subsets. Immunology 2007;122:486-95.
13. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20: what do B-cells do? Clin Immunol 2005;117:207-13.
14. Silverman GJ, Boyle DL. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev 2008;223:175-85.
15. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004;172:3422-7.
16. Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008;127:280-5.
17. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489-501.
18. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007;123:66-73.
19. Schmidt D, Martens PB, Weyand CM, Goronzy JJ. The repertoire of CD4+ CD28- T cells in rheumatoid arthritis. Mol Med 1996;2:608-18.
20. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 1997;40:1106-14.
21. Saadawi AM, L'Faqihi F, Diab BY, Sol MA, Enault G, Coppin H, et al. Dominant clones in immortalized T-cell lines from rheumatoid arthritis synovial membranes. Tissue Antigens 1997;49:431-7.
22. Malavasi F, Deaglio S, Ferrero E, Funaro A, Sancho J, Ausiello CM, et al. CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. Mol Med 2006;12: 334-41.
23. Zhang L, Miller RG, Zhang J. Characterization of apoptosisresistant antigen-specific T cells in vivo. J Exp Med 1996;183: 2065-73.